The “International Seminar on the Latest Advances in Precise Targeted Diagnosis and Treatment of Prostate Cancer and Neuroendocrine Tumor” was held in the First Affiliated Hospital of Xi’an Jiaotong University on June 4, 2018. Dr. Levente Meszaros, an expert in radioactive labeling for PRRT radionuclide diagnosis and treatment technology of oncology from St Thomas' Hospital of King's College London, UK attended the seminar under invitation, and the Directors and some doctors of relevant professions of our hospital attended this seminar.
Dr. Levente Meszaros introduced the situations of precise molecule targeted radionuclide diagnosis and treatment of prostate cancer and development experience in UK. Wang Guanli, the General Manager of Xi’an Liou Medical Technology Co., Ltd. introduced the clinical application of the latest integration of precise targeted radionuclide diagnosis and treatment in neuroendocrine neoplasm, prostatic cancer, bone metastasis cancer and various cancer fields and its developments in the world. Director Li Enxiao and Pro. Yang Jin from Medical Oncology Department, Pro. Duan Xiaoyi, Director of PET/CT Imaging Center, Pro. Yang Aimin, Director of Nuclear Medicine Department, Pro, Ma Mao, Director of Physical Examination Center, and Dr. Zhang Lingxiao and Dong Xuyuan from Medical Oncology Department and other doctors engaged in thorough discussions on the applications, development prospects and trends of the most cutting-edge “peptide receptor radionuclide imaging technology” and “peptide receptor radionuclide therapy technology” in the field of solid tumor.
Director Shi Bingyin took the time in his busy schedule to meet Dr. Levente Meszaros and participated in the discussion.
At present, the technology has been applied in only two hospitals (in Beijing and Nanning) in China. Since the “peptide receptor radionuclide imaging and treatment” is a kind of therapy technology reflecting the integration of precise targeted diagnosis and treatment, and the international cutting-edge new medicine and new technology that can be realized, it is of significant and imperative to promote and improve PET/CT, nuclear medicine, medical oncology, urinary surgery and other relevant subjects.
